ES2535437T3 - Métodos para tratar el mieloma múltiple utilizando terapias combinadas basadas en anticuerpos anti-CS1 - Google Patents

Métodos para tratar el mieloma múltiple utilizando terapias combinadas basadas en anticuerpos anti-CS1

Info

Publication number
ES2535437T3
ES2535437T3 ES07840746.7T ES07840746T ES2535437T3 ES 2535437 T3 ES2535437 T3 ES 2535437T3 ES 07840746 T ES07840746 T ES 07840746T ES 2535437 T3 ES2535437 T3 ES 2535437T3
Authority
ES
Spain
Prior art keywords
huluc63
bortezomib
dose
patients
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES07840746.7T
Other languages
English (en)
Spanish (es)
Inventor
Daniel Afar
Kenneth C. Anderson
Yu-Tzu Tai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
AbbVie Biotherapeutics Inc
Original Assignee
Dana Farber Cancer Institute Inc
AbbVie Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38831279&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2535437(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dana Farber Cancer Institute Inc, AbbVie Biotherapeutics Inc filed Critical Dana Farber Cancer Institute Inc
Application granted granted Critical
Publication of ES2535437T3 publication Critical patent/ES2535437T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2806—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
ES07840746.7T 2006-08-07 2007-08-07 Métodos para tratar el mieloma múltiple utilizando terapias combinadas basadas en anticuerpos anti-CS1 Active ES2535437T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US83618506P 2006-08-07 2006-08-07
US836185P 2006-08-07
US94426207P 2007-06-15 2007-06-15
US944262P 2007-06-15
PCT/US2007/075403 WO2008019378A1 (en) 2006-08-07 2007-08-07 Methods of treating multiple myeloma using combination therapies based on anti-cs1 antibodies

Publications (1)

Publication Number Publication Date
ES2535437T3 true ES2535437T3 (es) 2015-05-11

Family

ID=38831279

Family Applications (2)

Application Number Title Priority Date Filing Date
ES07840746.7T Active ES2535437T3 (es) 2006-08-07 2007-08-07 Métodos para tratar el mieloma múltiple utilizando terapias combinadas basadas en anticuerpos anti-CS1
ES13168383.1T Active ES2589302T3 (es) 2006-08-07 2007-08-07 Métodos de tratamiento de mieloma múltiple utilizando terapias de combinación basadas en HuLuc63 con bortezemib

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES13168383.1T Active ES2589302T3 (es) 2006-08-07 2007-08-07 Métodos de tratamiento de mieloma múltiple utilizando terapias de combinación basadas en HuLuc63 con bortezemib

Country Status (23)

Country Link
US (4) US8632772B2 (enExample)
EP (5) EP2641601B8 (enExample)
JP (1) JP5340935B2 (enExample)
CN (1) CN101686971B (enExample)
AU (1) AU2007281684C1 (enExample)
BR (1) BRPI0716647A2 (enExample)
CA (1) CA2660356C (enExample)
CY (5) CY1116247T1 (enExample)
DK (2) DK2641601T3 (enExample)
ES (2) ES2535437T3 (enExample)
HR (2) HRP20150449T1 (enExample)
HU (4) HUE029027T2 (enExample)
IL (2) IL196919A (enExample)
LT (4) LT2641601T (enExample)
LU (3) LU93277I2 (enExample)
MX (1) MX2009001441A (enExample)
NL (1) NL300840I2 (enExample)
NO (1) NO346835B1 (enExample)
NZ (1) NZ574978A (enExample)
PL (2) PL2641601T3 (enExample)
PT (2) PT2068874E (enExample)
SI (2) SI2068874T1 (enExample)
WO (1) WO2008019378A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2068874E (pt) 2006-08-07 2015-05-21 Abbvie Biotherapeutics Inc Métodos de tratamento de mieloma múltiplo utilizando terapias de combinação baseadas em anticorpos anti-csi
JP2010500370A (ja) 2006-08-07 2010-01-07 ピーディーエル バイオファーマ，インコーポレイティド 多発性硬化症を処置するための抗ｃｓ１抗体を用いる組成物および方法
CN102112147B (zh) 2008-06-02 2014-05-21 达纳-法伯癌症研究所股份有限公司 Xbp1、cd138、和cs1肽
KR20110028450A (ko) 2008-06-16 2011-03-18 이뮤노젠 아이엔씨 새로운 상승 효과
EA024364B1 (ru) * 2008-10-21 2016-09-30 Оникс Терапьютикс, Инк. Способ лечения множественной миеломы
ES2502541T3 (es) 2009-09-10 2014-10-03 Kyowa Hakko Kirin Co., Ltd. Medicamento que incluye una composición de anticuerpos unida específicamente al receptor 4 de quimiocina CC humana (CCR4)
CA2780998C (en) * 2009-11-24 2016-07-12 Celgene Corporation Immunomodulatory compounds for the restoration of vitamin d sensitivity in vitamin d resistant tumor cells
CN102241773B (zh) * 2010-05-13 2014-05-14 四川大学 抗骨髓瘤细胞多克隆抗体及其制备方法
AU2013337247B2 (en) 2012-11-05 2018-08-09 Dana-Farber Cancer Institute, Inc. XBP1, CD138, and CS1 peptides, pharmaceutical compositions that include the peptides, and methods of using such peptides and compositions
ES2707057T3 (es) * 2013-11-06 2019-04-02 Bristol Myers Squibb Co Combinación de anticuerpos anti-KIR y anti-CS1 para tratar el mieloma múltiple
US20160264670A1 (en) 2013-11-06 2016-09-15 Bristol-Myers Squibb Company Immunotherapeutic dosing regimens and combinations thereof
WO2015075011A1 (en) * 2013-11-21 2015-05-28 F. Hoffmann-La Roche Ag ANTI-alpha-SYNUCLEIN ANTIBODIES AND METHODS OF USE
SMT202300081T1 (it) * 2014-08-22 2023-05-12 Celgene Corp Metodi di trattamento di mieloma multiplo con composti immunomodulatori in combinazione con anticorpi
WO2016049022A1 (en) * 2014-09-23 2016-03-31 Board Of Trustees Of Michigan State University Compositions and methods for modulating an immune response
US10365280B2 (en) 2014-10-02 2019-07-30 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating malignancies
JP2017537893A (ja) 2014-10-31 2017-12-21 アッヴィ・バイオセラピューティクス・インコーポレイテッド 抗ｃｓ１抗体および抗体薬結合体
US10302644B2 (en) 2014-11-04 2019-05-28 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating multiple myeloma
US20170355768A1 (en) * 2014-12-04 2017-12-14 Bristol-Myers Squibb Company Combination of anti-cs1 and anti-pd1 antibodies to treat cancer (myeloma)
PL3294769T3 (pl) 2015-05-13 2021-07-05 Morphosys Ag Leczenie szpiczaka mnogiego (mm)
PL3313528T3 (pl) 2015-06-29 2021-12-13 Bristol-Myers Squibb Company Schematy dawkowania immunoterapeutycznego obejmujące pomalidomid i przeciwciało anty-cs1 w leczeniu raka
CN109498799A (zh) * 2016-03-13 2019-03-22 曹帅 一种用于治疗骨髓增生、骨癌的药物组合物及其用途
US11124579B2 (en) 2017-03-29 2021-09-21 Agency For Science, Technology And Research Anti oligosaccharide antibody
CN111373246A (zh) * 2017-11-22 2020-07-03 希成生物医药 包括硼替佐米的聚合物纳米颗粒
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone
JP2022553821A (ja) 2019-11-05 2022-12-26 ブリストル－マイヤーズ スクイブ カンパニー Ｍ－タンパク質アッセイおよびその使用
CN115368462B (zh) * 2022-07-19 2026-01-02 合肥天港免疫药物有限公司 双特异性抗体及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL112969A (en) 1994-03-17 2001-05-20 Baxter Int Pharmaceutical compositions for the treatment of cancer comprising allogenic lymphocytes or their combination with a t-cell activator
JPH11511746A (ja) 1995-05-25 1999-10-12 バクスター、インターナショナル、インコーポレイテッド 同種幹細胞移植後の癌の同種細胞治療
US7968569B2 (en) * 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
CN1981761B (zh) * 2002-05-17 2011-10-12 细胞基因公司 使用免疫调节性化合物用于制备治疗和控制癌症和其它疾病药物中的应用及组合物
US20050025763A1 (en) 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
US7709610B2 (en) * 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
AU2005302083A1 (en) * 2004-11-04 2006-05-11 Fibron Limited Treatment of B-cell malignancies
JP2010500370A (ja) 2006-08-07 2010-01-07 ピーディーエル バイオファーマ，インコーポレイティド 多発性硬化症を処置するための抗ｃｓ１抗体を用いる組成物および方法
EP2069478A2 (en) 2006-08-07 2009-06-17 PDL BioPharma, Inc. Use of allogeneic effector cells and anti-cs1 antibodies for selective killing of multiple myeloma cells
PT2068874E (pt) 2006-08-07 2015-05-21 Abbvie Biotherapeutics Inc Métodos de tratamento de mieloma múltiplo utilizando terapias de combinação baseadas em anticorpos anti-csi

Also Published As

Publication number Publication date
LU93275I2 (fr) 2016-12-27
HUS1600044I1 (hu) 2016-12-28
US20170342150A1 (en) 2017-11-30
IL243933A0 (en) 2016-04-21
HUS1600045I1 (hu) 2016-12-28
LT2641601T (lt) 2016-10-10
PL2068874T3 (pl) 2015-06-30
IL196919A0 (en) 2009-11-18
CY1116247T1 (el) 2017-02-08
PL2641601T3 (pl) 2017-01-31
CY1117992T1 (el) 2017-05-17
JP5340935B2 (ja) 2013-11-13
PT2068874E (pt) 2015-05-21
WO2008019378A1 (en) 2008-02-14
EP2641601A1 (en) 2013-09-25
AU2007281684B2 (en) 2013-05-16
IL196919A (en) 2016-03-31
HUS1600043I1 (hu) 2016-12-28
LTPA2016029I1 (lt) 2016-11-10
US20160137735A1 (en) 2016-05-19
SI2641601T1 (sl) 2016-11-30
JP2010500371A (ja) 2010-01-07
CY2016038I1 (el) 2017-07-12
NO20090968L (no) 2009-04-30
NO346835B1 (no) 2023-01-23
AU2007281684C1 (en) 2013-12-19
CY2016037I1 (el) 2017-07-12
HUE029027T2 (en) 2017-01-30
NZ574978A (en) 2012-08-31
EP2641600A1 (en) 2013-09-25
LU93276I2 (fr) 2016-12-27
SI2068874T1 (sl) 2015-06-30
DK2641601T3 (en) 2016-08-22
LTC2068874I2 (lt) 2018-11-12
CY2016036I2 (el) 2017-07-12
EP2068874A1 (en) 2009-06-17
AU2007281684A1 (en) 2008-02-14
LTPA2016031I1 (lt) 2016-11-10
EP2942057A1 (en) 2015-11-11
US20140322201A1 (en) 2014-10-30
CA2660356C (en) 2016-04-05
PT2641601T (pt) 2016-10-14
US8632772B2 (en) 2014-01-21
LU93277I2 (fr) 2016-12-27
EP2641601B8 (en) 2016-09-21
NL300840I2 (enExample) 2017-01-03
EP3115049A1 (en) 2017-01-11
MX2009001441A (es) 2009-07-06
EP2068874B1 (en) 2015-01-28
US20080152646A1 (en) 2008-06-26
BRPI0716647A2 (pt) 2017-05-16
CN101686971B (zh) 2013-09-11
HK1129853A1 (en) 2009-12-11
HRP20161284T1 (hr) 2016-12-16
CN101686971A (zh) 2010-03-31
HRP20150449T1 (xx) 2015-06-05
DK2068874T3 (da) 2015-04-27
ES2589302T3 (es) 2016-11-11
CA2660356A1 (en) 2008-02-14
LTPA2016030I1 (lt) 2016-11-10
CY2016036I1 (el) 2017-07-12
EP2641601B1 (en) 2016-07-06

Similar Documents

Publication Publication Date Title
ES2535437T3 (es) Métodos para tratar el mieloma múltiple utilizando terapias combinadas basadas en anticuerpos anti-CS1
Chelakkot et al. Modulating glycolysis to improve cancer therapy
US20190255082A1 (en) Enhancement of cd47 blockade therapy by proteasome inhibitors
AU2010223058A1 (en) Kinase protein binding inhibitors
KR20140079831A (ko) 췌장암 및／또는 담도암 치료약
CN114224889A (zh) 西奥罗尼联合免疫检查点抑制剂在抗肿瘤治疗中的应用
US20190241660A1 (en) Immune-stimulating peptides and checkpoint inhibitors, and uses thereof for treating cancer
Wang et al. Effects of extracellular histones on left ventricular diastolic function and potential mechanisms in mice with sepsis
TW202245741A (zh) 使用s1p受體調節劑之治療方法
WO2020236890A1 (en) Treating chronic liver disease
Holliday et al. Osteoclast polarization and orthodontic tooth movement
US20230094843A1 (en) Pharmaceutical combination for treating tumors and application thereof
CN110776521A (zh) 一种1,2,4-三唑-1,3,4-噻二唑类化合物及其应用
CN121648140A (zh) 一种帕米膦酸盐在制备用于预防、缓解和/或治疗非小细胞肺癌的药物中的应用
Schnoor et al. Inflammatory mediators contributing to intestinal epithelial cell apoptosis and barrier disruption in IBD
HK1233169A1 (en) Combination therapies based on anti-cs1 antibodies for treating multiple myeloma
HK1189515B (en) Methods of treating multiple myeloma using combination therapies based on huluc63 with bortezomib
CN101919861A (zh) 苯甲酰胺衍生物在制备治疗艾滋病药物中的应用
HK1189515A (en) Methods of treating multiple myeloma using combination therapies based on huluc63 with bortezomib
Lerner et al. Beneficial response of cervical dystonia spasmodic torticollis to cidofovir, an acyclic phosphonate analog (s-1-3-hydroxy-2-phosphonylmethoxypropyl) of cytosine
HK1189516A (en) Methods of treating multiple myeloma using combination therapies based on anti-cs1 antibodies
HK1129853B (en) Methods of treating multiple myeloma using combination therapies based on anti-cs1 antibodies
CN101919846A (zh) N2,n5-双[2-(3,4-二甲氧苯基)乙基]-2,5-吡啶甲酰胺的药物应用
CN101890002A (zh) 一种苯丙噻吩衍生物在制备抗艾滋病毒药物中的应用